For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| General and administrative | 1,958,768 | 1,747,585 | ||
| Professional fees | 379,218 | 290,313 | ||
| Officers salary | 871,049 | 872,289 | ||
| Research and development | 165,758 | 164,374 | ||
| Total operating expenses | 3,374,793 | 3,074,561 | ||
| Loss from operations | -3,374,793 | -3,074,561 | ||
| Net change in unrealized apreciation on investment in gold bullion | -110,198 | - | ||
| Interest expense | 570,709 | 529,603 | ||
| Gain on sale of gold | 200,433 | - | ||
| Interest income | 11,518 | 71,396 | ||
| Net change in unrealized depreciation on investment in gold bullion | - | -133,829 | ||
| Total other income/(expenses) | -248,560 | -324,378 | ||
| Net (loss) before provision for income taxes | -3,623,353 | -3,398,939 | ||
| Net (loss) | -3,623,353 | -3,398,939 | ||
| Basic EPS | 0 | 0 | ||
| Diluted EPS | 0 | 0 | ||
| Basic Average Shares | 1,059,485,670 | 1,038,374,219 | ||
| Diluted Average Shares | 1,059,485,670 | 1,038,374,219 | ||
Kraig Biocraft Laboratories, Inc. (KBLB)
Kraig Biocraft Laboratories, Inc. (KBLB)